PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
1183491211	rs2112865	PMCID:PMC3845218	SV2C	Genotype AA is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	olanzapine
1444700702	rs1801131	PMID:24725652	MTHFR	Genotype GG is associated with increased Weight gain when treated with clozapine or olanzapine in people with schizoaffective disorder and Schizophrenia as compared to genotype GT.	yes	= 0.0481	39		Multiple groups, Caucasian, African-American, Other	Toxicity	false	In patients with first episode psychosis of European ethnicity only. Those with the GG genotype had a higher mean percentage weight change as compared to those with the GT genotype. Please note that alleles have been complemented to the plus chromosomal strand.	clozapine; olanzapine
1451335298	rs4728709	PMID:33378980	ABCB1	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
769173468	rs4436578	PMID:20375926	DRD2	Genotype CC is associated with increased risk of body weight gain when treated with clozapine, olanzapine or risperidone in people with Schizophrenia.	yes	= 0.001	460		East Asian	Toxicity	false	Patients were treated with one of the three drugs: clozapine(239), olanzapine (70),risperidone(170).  Treatment was for  avg of 48.2 +/- 27.8 months.	clozapine; olanzapine; risperidone
1183629449	rs1800497	PMID:23859574	ANKK1	Genotype AA is associated with increased risk of Headache when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to genotype GG.	yes	= 0.035	161		European	Toxicity	false	A higher frequency of individuals with headache were found to have the DRD2 A1/A1 (30%) genotype vs A2/A2 (9%). Those with the A1/A2 genotype were in between (20%). Here allele A is used to represent A1 which is less frequent in Caucasian populations and G to represent A2 which is the major allele in Caucasians.  P value <0.05 for Chi-Squared analysis for this association. Statistics given below are for multivariate analysis for factors contributing to headache.	olanzapine; quetiapine; risperidone
1184348818	rs13429709	PMID:24624910	GCG	Allele C is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia.	yes	= 0.00009	86		European	Other	false	Combined risk allele analysis with rs13429709 allele C and rs2268639 allele T. Weight gain in carriers of no risk alleles vs one risk allele was not statistically significant. Weight gain of carriers of no or one risk allele vs two, three or four risk alleles was significant (p<0.05). Weight gain was highest with 3 or 4 risk alleles.	clozapine; olanzapine
1449181797	rs518147	PMID:29441581	HTR2C	Genotype CC is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders or Schizophrenia as compared to genotypes CG + GG.	yes	= 0.048	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1451335303	rs7787082	PMID:33378980	ABCB1	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
981478537	rs3813929	PMID:22967772	HTR2C	Allele C is not associated with Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele T.	no	= 1.0	119		European	Toxicity	false	Mental Disorders included borderline-personality disorder, treatment-resistant depression, and bipolar disorder. No patients with schizophrenia were included in order to minimize the amount of previous antipsychotic exposure. p-value corrected for multiple testing. This gene is on the X chromosome, male patients have only one copy. Male and female patients were analyzed separately and together.	olanzapine
1183491203	rs2270927	PMCID:PMC3845218	SV2C	Genotype CC is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes CG + GG.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	olanzapine
1183491207	rs6874435	PMCID:PMC3845218	SV2C	Genotype AA is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	olanzapine
1451335308	rs2273697	PMID:33378980	ABCC2	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1451317900	rs5128	PMID:33378980	APOC3	Genotype CG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.	no	= 0.068	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	There was a trend for CG individuals to have an increased Vd/F compared to GG individuals.	olanzapine
981478544	rs518147	PMID:22967772	HTR2C	Allele G is not associated with Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele C.	no	= 0.6669	119		European	Toxicity	false	Mental Disorders included borderline-personality disorder, treatment-resistant depression, and bipolar disorder. No patients with schizophrenia were included in order to minimize the amount of previous antipsychotic exposure. p-value corrected for multiple testing. This gene is on the X chromosome, male patients have only one copy. Male and female patients were analyzed separately and together.	olanzapine
1447680089	rs10848635	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.32	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1451335313	rs4520	PMID:33378980	APOC3	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1448532551	CYP2D6*1; CYP2D6*92; CYP2D6*96	PMID:27251229	CYP2D6	CYP2D6 *92 + *96 are associated with decreased clearance of olanzapine in insect microsomes as compared to CYP2D6 *1.	not stated					Metabolism/PK	false	Kinetic parameters for CYP2D6*92 and 2D6*96 could not be detected.	olanzapine
1183632031	CYP2D6*1; CYP2D6*3; CYP2D6*4	PMID:11901361	CYP2D6	CYP2D6 *1/*3 + *1/*4 are associated with increased Weight gain when treated with olanzapine in men with Schizophrenia as compared to CYP2D6 *1/*1.	yes	= 0.0097	11		European	Toxicity	false		olanzapine
1449181811	rs12836771	PMID:29441581	HTR2C; MIR1264; MIR1912	Genotype GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AA + AG.	yes	= 0.042	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1451335320	rs13306278	PMID:33378980	COMT	Genotype CT is not associated with exposure to olanzapine in healthy individuals as compared to genotype CC.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1184348813	rs2268639	PMID:24624910	GLP1R	Allele T is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia.	yes	= 0.00009	86		European	Other	false	Only associated in combined risk allele analysis with rs13429709 allele C and rs2268639 allele T. Weight gain in carriers of no risk alleles vs one risk allele was not statistically significant. Weight gain of carriers of no or one risk allele vs two, three or four risk alleles was significant (p<0.05). Weight gain was highest with 3 or 4 risk alleles.	clozapine; olanzapine
1447680083	rs758723	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.40	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1449181819	rs7799039	PMID:29441581	LEP	Genotype AA is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AG + GG.	no	= 0.321	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
981502111	rs11240594	PMCID:PMC3055694	SLC26A9	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	yes	= 0.068	213		Multiple groups, White/European American; Black/African American; other	Dosage,Efficacy	false	Adjacent SNPs also showed evidence for association.  Associated allele is not clear; it is reported as the minor allele being associated with greater response.  dbSNP shows A to generally be the minor allele, but this is not the case in all populations.  Most of the study participants were of White or Black ancestry (for which A is reported to be the minor allele), but only a study subset was genotyped, and the population distribution is not clear.  GWAS p =1.4 x 10 (-7) for 492K SNPs, so Bonferroni-corrected p is 0.068 .	olanzapine
1448996989	rs3766522	PMID:22305490	PRKAB2	Genotype TT is associated with decreased severity of Weight gain when treated with antipsychotics, clozapine or olanzapine in people with schizoaffective disorder or Schizophrenia as compared to genotypes AA + AT.	yes	= 0.022	84		European	Toxicity	false	Authors state it was significant but it did not meet study-wide correction for multiple tests. CAUTION: this is a A/T SNP in a gene on the minus strand. Alleles were complemented to the plus chromosomal strand.	antipsychotics; clozapine; olanzapine
608431206	rs5443	PMID:19193342	GNB3	Allele T is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	not stated	= 0.043	164		East Asian	Toxicity	false		olanzapine
981502120	rs11677416	PMCID:PMC3055694	IL1A	Allele C is associated with increased response to olanzapine in people with Schizophrenia as compared to allele T.	yes	= 0.32	200		Multiple groups, White/European American; Black/African American; other	Dosage,Efficacy	false	Adjacent SNPs also showed evidence for association.  Associated allele is reported as the minor allele being associated with greater response.  dbSNP shows C to be the minor allele in all populations reported upon.   GWAS p = 6.6 x 10 (-7) for 492K SNPs, so Bonferroni-corrected p is 0.32 .	olanzapine
608431210	rs6313	PMID:19193342	HTR2A	Genotype GG is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotypes AA + AG.	not stated	= 0.0078	164		East Asian	Toxicity	false		olanzapine
1447813735	rs1076560	PMCID:PMC4915265	DRD2	Genotypes AA + AC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotype CC.	yes	< 0.04	63		Unknown	Efficacy	false	The associations were evaluated in conjunction with rs6314 in the HTR2A gene. rs1076560 GT/rs6314 CC diplotype was associated with better responses to antipsychotics than the rs1076560 GG/rs6314 CT diplotype	olanzapine
608431214	rs6318	PMID:19193342	HTR2C	Allele C is associated with increased severity of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype GG.	yes	= 0.48	164		East Asian	Toxicity	false	Authors state is significant but p=value shown on graph is not. This gene is on the X chromosome and males only have one copy. Study compared minor allele absent (G or GG) vs minor allele present (C, CG or CC), % change in BMI was greater (10%) for minor allele present (n=9) compared to 5% for no minor allele (n=153) although SD bars were large.	olanzapine
1451335340	rs4680	PMID:33378980	COMT	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1448632439	rs35694136	PMID:25090458	CYP1A2	Genotype T/del is associated with increased concentrations of olanzapine in people with Schizophrenia as compared to genotype TT.	yes	= 0.009	93		European	Metabolism/PK	false		olanzapine
1184136868	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:23859574	SLC6A4	SLC6A4 HTTLPR long form (L allele) is associated with increased risk of Dizziness when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	yes	= 0.015	206		European	Toxicity	false	The long allele was associated with increased likelihood of dizziness compared to patients with the short/short genotype. P value <0.05 for Chi-Squared analysis for this association. Statistics given below are for multivariate analysis for factors contributing to headache. The article used the SLC6A4 rs4795541 [5HTTLPR L/S] for identification. Historically a long insertion/deletion was submitted under this SNP. Currently, the rsnumber does not support a long insertion/deletion on dbSNP.	olanzapine; quetiapine; risperidone
1451335345	CYP1A2*1A; CYP1A2*1B; CYP1A2*1C; CYP1A2*1F	PMID:33378980	CYP1A2	CYP1A2 *1B + *1C + *1F are not associated with exposure to olanzapine in healthy individuals as compared to CYP1A2 *1A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. The following rsIDs were used to identify CYP1A2 star alleles: rs2470890 (identified *1B), rs2069514 (identifies *1C) and rs762551 (identifies *1F).	olanzapine
608431218	rs4994	PMID:19193342	ADRB3	Genotype GG is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotypes AA + AG.	not stated	= 0.024	164		East Asian	Toxicity	false		olanzapine
1448998508	rs3813929	PMID:20195292	HTR2C	Genotype TT is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotypes CC + CT.	no	= 0.002	101		European	Toxicity	false	but there were significant increases in waist circumference, fasting blood glucose, and triglycerides which are features of metabolic syndrome. NOTE: this is x-linked gene and authors chose to only investigate in women.	olanzapine; risperidone
655388451	rs1414334	PMID:20680028	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	yes	= 0.015	186		European	Toxicity	false	Note: this is an x-linked gene on plus strand. Male subjects have only one copy of the allele (C or G) whereas female subjects can be CC, CG or GG.	antipsychotics; aripiprazole; clozapine; olanzapine; quetiapine; risperidone
1451335348	rs4803419	PMID:33378980	CYP2B6	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1451335353	CYP2C8*1; CYP2C8*2; CYP2C8*3	PMID:33378980	CYP2C8	CYP2C8 *2 + *3 are not associated with exposure to olanzapine in healthy individuals as compared to CYP2C8 *1.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. The following rsIDs were used to identify CYP2C8 star alleles: rs11572103 (identifies *2), rs10509681 (identifies *3).	olanzapine
608431224	rs6280	PMID:18320559	DRD3	Genotype CC is associated with greater positive symptom improvement and positive symptom remission when treated with olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	yes	= 0.033	88		Multiple groups, White; Black; Latino	Efficacy	false		olanzapine
1451335358	CYP2C19 poor metabolizers and intermediate metabolizers	PMID:33378980	CYP2C19	CYP2C19 poor metabolizers and intermediate metabolizers are not associated with exposure to olanzapine in healthy individuals as compared to CYP2C19 normal metabolizers.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. The following rsIDs were used to identify CYP2C19 star alleles: rs4244285 (identifies *2), rs4986893 (identifies *3), rs28399504 (identifies *4) and rs12248560 (identifies *17).	olanzapine
1451335361	rs2279345	PMID:33378980	CYP2B6	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
827829013	rs11872992	PMID:22310352	MC4R	Allele G is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	no	= 0.1	136		European	Other	false	Trend only.	clozapine; olanzapine
655388500	rs1799732	PMID:16513877	DRD2	Allele del is associated with increased time to respond when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype GG.	yes	< 0.03	61		Multiple groups, 41% African American; 28% Caucasian (European); 18% Hispanic; 5% Asian; 8% other	Efficacy	false	olanzapine (2.5 to 20 mg/day, N=28) or risperidone (1to 6 mg, N=33) treatment	olanzapine; risperidone
1450815036	rs10170310	PMCID:PMC3922978	SPOPL	Allele C is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele A.	yes	= 1.03E-07	173		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of G alleles present in a patient was positively associated with PGI score.	olanzapine
1448632350	rs61750900	PMID:21750471	UGT2B10	Genotypes GT + TT is associated with decreased glucuronidation of olanzapine in experiments with expressed proteins and HLMs as compared to genotype GG.	yes	= 0.0002	95		Unknown	Metabolism/PK	false	this increase was for both olanzapine 10-n-glucuronide and olanzapine 4-n-glucuronide.	olanzapine
827829008	rs17782313	PMID:22310352	MC4R	Allele C is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele T.	no	= 0.09	144		European	Other	false	Trend only	clozapine; olanzapine
655388504	rs1799978	PMID:16513877	DRD2	Allele C is associated with decreased time until response when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype TT.	yes	= 0.004	61		Multiple groups, 41% African American; 28% Caucasian (European); 18% Hispanic; 5% Asian; 8% other	Efficacy	false	olanzapine (2.5 to 20 mg/day, N=28) or risperidone (1to 6 mg, N=33) treatment	olanzapine; risperidone
1448632338	UGT1A4*1a; UGT1A4*2	PMID:21750471	UGT1A4	UGT1A4 *2 is not associated with increased glucuronidation of olanzapine in experiments with HLMs as compared to UGT1A4 *1a.	no					Metabolism/PK	false	"although in experiments with expressed proteins the *2 variant had lower Vmax for formation of olanzapine 10-n-glucuronide but this had no effect in the HLMs. Authors state ""no significant difference in formation of any OLZ glucuronide was observed when comparing those homozygous for the UGT1A424Thr/48Leu allele [UGT1A4 (*2/*2) genotype; n=2] to HLM homozygous for the UGT1A424Pro/48Leu allele [UGT1A4 (*1/*1) genotype; n=73], even after excluding HLM with one or more UGT1A4*3 (UGT1A424Pro/48Val) alleles (results not shown)."""	olanzapine
1448998934	rs6318	PMID:20504252	HTR2C	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false	Groups compared were GG females plus G males vs CG females + CC females + C males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
978639387	rs2011425	PMID:22713701	UGT1A4	Genotypes GG + GT are associated with increased glucuronidated metabolites of olanzapine when treated with olanzapine as compared to genotype TT.	yes	< 0.01	129		Multiple groups	Metabolism/PK	false	with an increase of 11.2 units (+38.3%; P = 0.011) in glucuronide concentrations in heterozygous carriers of UGT1A4*3 (GT) and an increase of 72.2 units (+246%; P< 0.001) in patients homozygous (GG) for UGT1A4*3.	olanzapine
1183689438	CYP1A2*1A; CYP1A2*1F	PMID:18223460	CYP1A2	CYP1A2 *1F is not associated with differences in plasma OLZ and metabolite concentrations and on their respective ratios when treated with olanzapine in people with Schizophrenia as compared to CYP1A2 *1A.	no	> 0.05	51		East Asian	Metabolism/PK	false		olanzapine
1448998926	rs7566605	PMID:20504252	INSIG2	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1183689429	CYP2D6*1; CYP2D6*10	PMID:18223460	CYP2D6	CYP2D6 *10 is not associated with differences in plasma OLZ and metabolite concentrations and on their respective ratios when treated with olanzapine in people with Schizophrenia as compared to CYP2D6 *1.	no	> 0.05	51		East Asian	Metabolism/PK	false		olanzapine
637879900	rs1079598	PMID:20714340	DRD2	Allele G is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	not stated	= 0.003	85		European	Toxicity	false		clozapine; olanzapine
1448632322	UGT1A4*1a; UGT1A4*3a	PMID:21750471	UGT1A4	UGT1A4 *3a is associated with increased glucuronidation of olanzapine in experiments with expressed proteins and HLMs as compared to UGT1A4 *1a.	yes	= 0.0013	92		Unknown	Metabolism/PK	false	this increase was for both olanzapine 10-n-glucuronide and olanzapine 4-n-glucuronide.	olanzapine
1448998918	rs17047764	PMID:20504252	INSIG2	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
637879896	rs1800497	PMID:20714340	ANKK1	Allele A is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele G.	not stated	= 0.046	85		European	Toxicity	false		clozapine; olanzapine
1183703789	CYP3A5*1; CYP3A5*3	PMID:23559402	CYP3A5	CYP3A5 *1/*1 + *1/*3 is associated with increased area under the curve when exposed to olanzapine in healthy individuals as compared to CYP3A5 *3/*3.	yes	< 0.05	63		European	Metabolism/PK	false	Patients with the *1/*1 or *1/*3 genotypes had increased area under the curve for the time of administration to the last measured concentration (AUC0-t), as compared to those with the *3/*3 genotype. This difference was significant in univariate analysis and multiple regression analysis.	olanzapine
1183689454	rs2011425	PMID:18223460	UGT1A4	Allele G is not associated with differences in plasma OLZ and metabolite concentrations and on their respective ratios when treated with olanzapine in people with Schizophrenia as compared to allele T.	no	> 0.05	51		East Asian	Metabolism/PK	false		olanzapine
827828530	rs324420	PMID:20631561	FAAH	Allele A is associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	yes	= 0.002	83		European	Toxicity	false	weight gain of more than 7% of baseline body weight	aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
637879906	rs6277	PMID:20714340	DRD2	Allele G is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	not stated	= 0.027	85		European	Toxicity	false		clozapine; olanzapine
1183689446	CYP1A2*1A; CYP1A2*1C	PMID:18223460	CYP1A2	CYP1A2 *1C is not associated with differences in plasma OLZ and metabolite concentrations and on their respective ratios when treated with olanzapine in people with Schizophrenia as compared to CYP1A2 *1A.	no	> 0.05	51		East Asian	Metabolism/PK	false		olanzapine
1451335402	CYP2C19 ultrarapid metabolizer	PMID:33378980	CYP2C19	CYP2C19 ultrarapid metabolizer are not associated with exposure to olanzapine in healthy individuals as compared to CYP2C19 normal metabolizers.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. The following rsIDs were used to identify CYP2C19 star alleles: rs4244285 (identifies *2), rs4986893 (identifies *3), rs28399504 (identifies *4) and rs12248560 (identifies *17).	olanzapine
827828539	rs1049353	PMID:20631561	CNR1	Allele T is not associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	no	= 0.7	83		European	Toxicity	false	weight gain of more than 7% of baseline body weight	aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1451335406	CYP2D6 ultrarapid metabolizer	PMID:33378980	CYP2D6	CYP2D6 ultrarapid metabolizer is not associated with exposure to olanzapine in healthy individuals as compared to CYP2D6 normal metabolizers.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. The following rsIDs were used to identify CYP2D6 star alleles: rs35742686 (identifies *3), rs3892097 (identifies *4), rs5030655 (identifies *6), rs5030867 (identifies *7), rs5030865 (identifies *8), rs5030656 (identifies *9), rs1065852 (identifies *10), rs5030865 (identifies *14), rs28371706 (identifies *17), rs28371725 (identifies *41).	olanzapine
1183703807	rs1799735	PMID:23559402	GSTM3	Genotype CCT/CCT is associated with decreased area under the curve when exposed to olanzapine in healthy individuals as compared to genotypes CCT/del + del/del.	yes	< 0.05	63		European	Metabolism/PK	false	CCT = *A and del = *B. This result was ONLY significant in univariate analysis, and NOT significant in multiple regression analysis.	olanzapine
1448532517	CYP2D6*1; CYP2D6*10; CYP2D6*87; CYP2D6*88; CYP2D6*90; CYP2D6*91; CYP2D6*93; CYP2D6*95; CYP2D6*97	PMID:27251229	CYP2D6	CYP2D6 *10 + *87 + *88 + *90 + *91 + *93 + *95 + *97 are associated with decreased clearance of olanzapine as compared to CYP2D6 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	The the conversion of olanzapine to 2-hydroxymethylolanzapine was measured for *2 (R296C, S486T); *10 (P34S, S486T); *87 (A5V); *88 (V104A); *89 (L142S); *90 (K147R); *91 (C161S); *93 (T249P); *94 (D337G); *95(R388H); *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1.  No information about *1 construct but might be cDNA. Clearance in % *10: 5.2 *87: 26.0 *88: 78.9 *90: 75.8 *91: 75.7 *93: 17.7 *95: 68.4 *97: 75.3. Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.	olanzapine
1451335410	CYP2D6 poor metabolizers and intermediate metabolizers	PMID:33378980	CYP2D6	CYP2D6 poor metabolizers and intermediate metabolizers is not associated with exposure to olanzapine in healthy individuals as compared to CYP2D6 normal metabolizers.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. The following rsIDs were used to identify CYP2D6 star alleles: rs35742686 (identifies *3), rs3892097 (identifies *4), rs5030655 (identifies *6), rs5030867 (identifies *7), rs5030865 (identifies *8), rs5030656 (identifies *9), rs1065852 (identifies *10), rs5030865 (identifies *14), rs28371706 (identifies *17), rs28371725 (identifies *41).	olanzapine
1183703802	rs1799735	PMID:23559402	GSTM3	Genotype CCT/CCT is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes CCT/del + del/del.	yes	< 0.05	63		European	Metabolism/PK	false	CCT = *A and del = *B. This result was significant in univariate analysis and multiple regression analysis.	olanzapine
1450814990	rs6688363	PMCID:PMC3922978	ATP1A2	Allele T is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele C.	yes	= 1.59E-07	173		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of T alleles present in a patient was positively associated with CGI-S score.	olanzapine
1451335416	rs1800497	PMID:33378980	ANKK1; DRD2	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. This variant is referred to in the paper as the Taq1A variant.	olanzapine
769171364	rs1801282	PMID:19622037	PPARG	Genotype CG is associated with increased Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	yes	= 0.012	95		Near Eastern	Other	false	Increased weight gain, and change in Body Mass Index. Polymorphism is referred to in the study as Pro12Ala (CCA>GCA), therefore GC corresponds to the Pro/Ala genotype and CC to Pro/Pro.	olanzapine
1448998945	rs2929183	PMID:20732371	CCKBR	Genotype AA is associated with decreased severity of Weight gain when treated with clozapine or olanzapine in people with schizoaffective disorder or Schizophrenia as compared to genotypes AG + GG.	no	= 0.035	87		European	Toxicity	false	Authors considered this marginal/trend and effect was for opposite allele in patients with African ancestry.	clozapine; olanzapine
1451335420	CYP3A4*1; CYP3A4*22	PMID:33378980	CYP3A4	CYP3A4 *22 is not associated with exposure to olanzapine in healthy individuals as compared to CYP3A4 *1.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. rs35599367 was used to identify the *22 allele.	olanzapine
1448632358	rs2011425	PMID:20143052	UGT1A4	Genotype GT is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotype TT.	yes	= 0.019	102		Unknown	Metabolism/PK	false	although this did not translate to numbers of patients below the therapeutic interval. No GG homozygotes were observed.	olanzapine
978639403	rs2011425	PMID:22713701	UGT1A4	Genotypes GG + GT are not associated with serum concentrations of the parent drug olanzapine when treated with olanzapine as compared to genotype TT.	no	= 0.405	407		Multiple groups	Metabolism/PK,Other	false		olanzapine
608431299	rs4731426	PMID:18681781	LEP	Genotype GG is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	yes	= 0.019	130		Central/South Asian	Toxicity	false		olanzapine
981488640	rs2734842	PMID:21095016	DRD2	Allele G is associated with increased prolactin when treated with olanzapine in women as compared to allele C.	yes	= 0.0034	77	21	European	Metabolism/PK,Other	false	These women had mild to moderate mania or bipolar I depression or treatment-resistant depression.  In men, there was non-significant association but in the other direction.  The association in women was stated as being with the negative strand allele C, and was with larger increases in prolactin.  Authors discuss that a smaller number of men in the study may explain the lack of significant association found in men.	olanzapine
1446898364	rs489693	PMID:23920449	MC4R	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	yes	= 0.017	86		Unknown	Other	false	The authors analyzed the whole population of all patients administered one of many anti-psychotics, then a subpopulation without additional weight gain-inducing co-medication (adjusted sub-population)(weight-gaining co-meds included TCA, mirtazapine, lithium, valproic acid, and paroxetine) as well as a sub-group of patients for whom anti-psychotics were given for a first episode.The authors calculated adjusted means for weight gain 4 wk post-initiation of medication using ANCOVA and rs489693 genotype as a independent variable. Patients with the AA genotype had between 2.2–3.1 higher increase in weight gain vs. patients with the CC genotype.	amisulpride; clozapine; olanzapine; paliperidone; quetiapine; risperidone
1448639707	rs7412	PMCID:PMC5600660	APOE	Allele C is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele T.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
981478404	rs7877	PMID:23147717	FMO1	Genotypes CT + TT are associated with increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to genotype CC.	yes	= 0.04	379		European	Metabolism/PK	false	"Data was from therapeutic drug monitoring service and disease indication for drug use is not specified beyond ""psychiatric patients"". This was more significant when considered with rs12720462A, and more pronounced in smokers."	olanzapine
981488647	rs6275	PMID:21095016	DRD2	Allele A is associated with increased prolactin when treated with olanzapine in women as compared to allele G.	yes	= 0.0015	77	21	European	Metabolism/PK,Other	false	These women had mild to moderate mania or bipolar I depression or treatment-resistant depression.  In men, there was non-significant association but in the other direction.  The association in women was with larger increases in prolactin.  Authors discuss that a smaller number of men in the study may explain the lack of significant association found in men.	olanzapine
1451550220	rs362719	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no	= 0.732	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448639698	rs429358	PMCID:PMC5600660	APOE	Allele C is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele T.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
981488655	rs6279	PMID:21095016	DRD2	Allele G is associated with increased prolactin when treated with olanzapine in women as compared to allele C.	yes	= 8.0E-4	77	21	European	Metabolism/PK,Other	false	These women had mild to moderate mania or bipolar I depression or treatment-resistant depression.  In men, there was non-significant association but in the other direction.  The association in women was stated as being with the negative strand allele C, and was with larger increases in prolactin.  Authors discuss that a smaller number of men in the study may explain the lack of significant association found in men.	olanzapine
982015513	rs1880676	PMID:17503482	CHAT	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	yes	= 0.12	84		European	Dosage,Efficacy	false	This association was nominally significant (p= 0.04) in the Spanish cohort but not in the Basque cohort, but if corrected for the 3 SNPs tested, p = 0.12.	olanzapine
1448639689	rs699	PMCID:PMC5600660	AGT	Allele G is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele A.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
981501459	rs1049353	PMCID:PMC3055343	CNR1	Genotype CC is associated with decreased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotype CT.	no	= 0.86	41		African American/Afro-Caribbean	Toxicity	false	"This was a nominal association that did not survive correction for multiple testing.  The weight gain was 8.4 +/- 7.59 vs 16.05 +/- 8.29.  The association was found in the African -American ancestry patient subset of this study but not in a larger set that included patients of European ancestry and ""others""."	clozapine; olanzapine
1451550226	rs7341475	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	no	= 0.978	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
981488663	rs1124493	PMID:21095016	DRD2	Allele T is associated with increased prolactin when treated with olanzapine in women as compared to allele G.	yes	= 0.0029	77	21	European	Metabolism/PK,Other	false	These women had mild to moderate mania or bipolar I depression or treatment-resistant depression.  In men, there was non-significant association but in the other direction.  The association in women was with larger increases in prolactin.  Authors discuss that a smaller number of men in the study may explain the lack of significant association found in men.	olanzapine
1451550232	rs39339	PMCID:PMC7005197	RELN	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.841	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
981500957	rs25531	PMID:20031235	SLC6A4	Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T.	no		147		European	Efficacy	false	6 week response was assessed.	antipsychotics; haloperidol; olanzapine; risperidone
981488671	rs2734841	PMID:21095016	DRD2	Allele A is associated with increased prolactin when treated with olanzapine in women as compared to allele C.	yes	= 0.0047	77	21	European	Metabolism/PK,Other	false	These women had mild to moderate mania or bipolar I depression or treatment-resistant depression.  In men, there was non-significant association but in the other direction.  The association in women was with larger increases in prolactin.  Authors discuss that a smaller number of men in the study may explain the lack of significant association found in men.	olanzapine
981858853	rs2472297	PMID:23492908	CYP1A1	Allele T is associated with 25% higher mean 4'-desmethyl OLA/olanzapine (OLA) ratio when treated with olanzapine in people with Psychotic Disorders as compared to genotype CC.	yes	= 1.0E-4	342		European	Metabolism/PK	false		olanzapine
1183629357	rs1800497	PMID:23859574	ANKK1	Genotype AA is associated with increased Drug Toxicity when treated with olanzapine in healthy individuals as compared to genotypes AG + GG.	not stated	= 0.031	58		European	Toxicity	false	Individuals with the DRD2 A1/A1 genotype more frequently developed adverse reactions (80%) vs A1/A2 (28%) and A2/A2 (23%). Here allele A is used to represent A1 which is less frequent in Caucasian populations  and G to represent A2 which is the major allele in Caucasians). Statistics did not mention correction for multiple testing.	olanzapine
1451550247	rs3808035	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	no	= 0.695	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1451550241	rs3819479	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.529	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
981858860	rs4410790	PMID:23492908	AHR	Allele T is associated with 29% lower mean 4'-desmethyl OLA/olanzapine (OLA) ratio when treated with olanzapine in people with Psychotic Disorders as compared to genotype CC.	yes	= 0.001	342		European	Metabolism/PK	false		olanzapine
1451550253	rs2535764	PMCID:PMC7005197	RELN	Allele T is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no	= 0.179	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
981477934	rs3813929	PMID:17702092	HTR2C	Allele T is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele C.	no		139		Unknown	Toxicity	false	This SNP was studied in conjunction with rs6318 and a repeat polymorphism in the 5' flanking region [(GT)12-18/(CT)4-5].  None of the three variants were associated with increased risk of weight gain when studied alone.  When studied as a combination, only one combination, the long-C-Ser (repeat-rs3813929-rs6318), was associated with a protective effect against weight gain.  However, effect and sample sizes were small (n=13). This gene is on the X chromosome therefore males have one copy, the percentages of males in the study size was not reported.	clozapine; haloperidol; olanzapine; risperidone
1183689276	CYP2D6 poor metabolizer	PMID:12640212	CYP2D6	CYP2D6 poor metabolizer is not associated with difference in the dose-normalized steady-state plasma concentration of olanzapine when treated with olanzapine in people with Mental Disorders as compared to CYP2D6 normal metabolizer.	no	= 0.1	17		Unknown	Metabolism/PK	false	Patients were phenotyped with debrisoquine.	olanzapine
1448998639	rs3813929	PMID:18718676	HTR2C	Allele T is not associated with increased Weight gain when treated with olanzapine or risperidone in women with Schizophrenia as compared to allele C.	no	= 0.057	49	59	European	Toxicity	false	HTR2C gene is x-linked, study was performed in women only.	olanzapine; risperidone
981477941	rs6318	PMID:17702092	HTR2C	Allele C is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele G.	no		139		Unknown	Toxicity	false	This SNP was studied in conjunction with rs3813929 and a repeat polymorphism in the 5' flanking region [(GT)12-18/(CT)4-5].  None of the three variants were associated with increased risk of weight gain when studied alone.  When studied as a combination, only one combination, the long-C-Ser (repeat-rs3813929-rs6318), was associated with a protective effect against weight gain.  However, effect and sample sizes were small (n=13). This gene is on the X chromosome therefore males have one copy, the percentages of males in the study size was not reported.	clozapine; haloperidol; olanzapine; risperidone
981858866	rs762551	PMID:23492908	CYP1A2	Allele A is not associated with olanzapine exposure when treated with olanzapine in people with Psychotic Disorders as compared to allele C.	no		342		European	Metabolism/PK	false		olanzapine
1451550259	rs12705169	PMCID:PMC7005197	RELN	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.596	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1183689269	CYP2D6 poor metabolizer	PMID:11699614	CYP2D6	CYP2D6 poor metabolizer is not associated with significant differences in any of the olanzapine pharmacokinetic parameters when exposed to olanzapine in healthy individuals as compared to CYP2D6 normal metabolizer.	no		17		European	Metabolism/PK	false	Subjects were phenotyped with dextrometorphan. Single dose of olanzapine.	olanzapine
1451550271	rs362626	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	no	= 0.394	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1451317820	rs34059508	PMID:33378980	SLC22A1	Genotype AG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.	yes	= 0.004	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	The A allele is referred to in the paper as SLC22A1*5. Participants with the *1/*5 genotype had a significantly increased AUC and Cmax compared to *1/*1.	olanzapine
1451550265	rs2237628	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.160	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
982015543	rs3810950	PMID:17503482	CHAT	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	no	= 0.18	166		European	Dosage,Efficacy	false	This association was described as a trend.  Uncorrected p = 0.061; corrected p = 0.18.	olanzapine
1451439680	rs2740574	PMID:23559402	CYP3A4	Genotypes CC + CT is associated with increased likelihood of dry mouth when exposed to olanzapine in healthy individuals as compared to genotype TT.	yes	= 0.023	63		European	Toxicity	false	A greater percentage of patients with the *1/*1B or *1B/*1B genotype experienced dry mouth after administration of olanzapine, as compared to those with the *1/*1 genotype. This was ONLY significant using the chi-squared test, and was NOT significant using logistic regression. Mapped *1B to rs2740574 C and *1A to rs2740574 T based on PharmVAR consolidation of core alleles.	olanzapine
1183689285	CYP2D6*1; CYP2D6*4	PMID:19000940	CYP2D6	CYP2D6 *4 is not associated with response to olanzapine in people with Schizophrenia as compared to CYP2D6 *1.	no		130		Central/South Asian	Efficacy	false	no p-value reported	olanzapine
1451550286	rs362813	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.903	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448998550	rs2032582	PMID:20195292	ABCB1	Genotype AA is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotypes AC + CC.	no	= 0.001	101		European	Toxicity	false	in fact A allele was slightly less common in patients without metabolic syndrome than with metabolic syndrome but there were significant increases in fasting blood glucose in AA homozygotes (particularly in olanzapine subset) and glucose dysregulation is a feature of metabolic syndrome. Alleles complemented to plus chromosomal strand.	olanzapine; risperidone
1451550280	rs362814	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.973	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
608431246	rs2842030	PMCID:PMC2194758	RGS4	Genotype TT is associated with increased response to olanzapine and perphenazine in people with Schizophrenia as compared to genotypes GG + GT.	not stated	= 0.05	198		Unknown	Efficacy	false	compared to quetiapine, risperidone or ziprasidone based on Positive and Negative Syndrome Scale (PANSS) positive scores	olanzapine; perphenazine
1447813766	rs6314	PMCID:PMC4915265	HTR2A	Genotype GG is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes AA + AG.	yes	= 0.04	63		European	Efficacy	false	The associations were evaluated in conjunction with rs1076560 in the DRD2 gene. rs1076560 GT/rs6314 CC diplotype was associated with better responses to antipsychotics than the rs1076560 GG/rs6314 CT diplotype	olanzapine
1451550292	rs362731	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.134	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1184469067	rs7912580	PMID:24751813		Genotype AG is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype GG.	no	> 0.05	1406		Unknown	Efficacy	false	results did not reach significance.	olanzapine; quetiapine; risperidone; ziprasidone
1448632458	rs762551	PMID:25090458	CYP1A2	Genotype AA is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotypes AC + CC.	yes	= 0.038	98		European	Metabolism/PK	false	but this was only significant for dose-adjusted serum concentrations, not dose and body weight adjusted serum concentrations.	olanzapine
1183689310	rs6280	PMID:19000940	DRD3	Allele T is not associated with response to olanzapine in people with Schizophrenia as compared to allele C.	no		130		Central/South Asian	Efficacy	false	no p-value reported	olanzapine
1448997001	rs10789038	PMID:22305490	PRKAA2	Genotype AA is associated with decreased severity of Weight gain when treated with antipsychotics, clozapine or olanzapine in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.	yes	= 0.023	84		European	Toxicity	false	Authors state it was significant but it did not meet study-wide correction for multiple tests.	antipsychotics; clozapine; olanzapine
1183689306	rs6313	PMID:19000940	HTR2A	Allele G is not associated with response to olanzapine in people with Schizophrenia as compared to allele A.	no		130		Central/South Asian	Efficacy	false	no p-value reported	olanzapine
1451550301	rs362726	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.862	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448632450	rs2011425	PMID:25090458	UGT1A4	Allele G is not associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to allele T.	no	= 0.638	93		European	Metabolism/PK	false	no GG homozygotes were observed.	olanzapine
1451335261	rs2032582	PMID:33378980	ABCB1	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
1183689298	CYP1A2*1A; CYP1A2*1F	PMID:19000940	CYP1A2	CYP1A2 *1F is not associated with response to olanzapine in people with Schizophrenia as compared to CYP1A2 *1A.	no		130		Central/South Asian	Efficacy	false	no p-value reported	olanzapine
1448998530	rs1045642	PMID:20195292	ABCB1	Genotypes AG + GG is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotype AA.	no	= 0.028	61		European	Toxicity	false	but there were significant increases in fasting blood glucose in olanzapine treated patients with the AG+GG genotypes and glucose dysregulation is a feature of metabolic syndrome. Alleles complemented to plus chromosomal strand.	olanzapine; risperidone
981478496	rs2440390	PMID:22967772	DRD2	Allele T is associated with increased Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele C.	yes	= 0.0473	117		European	Toxicity	false	Mental Disorders included borderline-personality disorder, treatment-resistant depression, and bipolar disorder. No patients with schizophrenia were included in order to minimize the amount of previous antipsychotic exposure. p-value corrected for multiple testing. Please note that alleles have been complemented to the plus chromosomal strand.	olanzapine
1451335266	rs2032582	PMID:33378980	ABCB1	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
1449181828	rs1137101	PMID:29441581	LEPR; LEPROT	Genotype GG is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AA + AG.	no	= 0.816	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1184348786	rs13429709	PMID:24624910	GCG	Genotype CC is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotype TT.	yes	= 0.044	87		European	Other	false	Weight gain was highest in CC>TC>TT. This was only significant in the European subset of patients treated with clozapine/olanzapine. No significant association was seen in a larger combined sample of 3 studies with patients on antipsychotics.	clozapine; olanzapine
1451335271	rs10248420	PMID:33378980	ABCB1	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
655387127	rs951439	PMCID:PMC2194758	RGS4	Genotype CC is associated with increased likelihood of positive response when treated with olanzapine and perphenazine in people with Schizophrenia as compared to genotypes CT + TT.	yes	= 0.002	198		Unknown	Efficacy	false	compared to ziprasidone.	olanzapine; perphenazine
1183491171	rs11960832	PMCID:PMC3845218	SV2C	Genotype TT is associated with decreased response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 0.0218	134		European	Efficacy	false	Response was assessed by a change in the total Positive and Negative Syndrome Scale (PANSS) score. TT homozygotes had a smaller decrease or an increase in PANSS score compared to C allele carriers.	olanzapine
981478506	rs6318	PMID:22967772	HTR2C	Allele G is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele C.	yes	= 0.0032	73		European	Toxicity	false	Mental Disorders included borderline-personality disorder, treatment-resistant depression, and bipolar disorder. No patients with schizophrenia were included in order to minimize the amount of previous antipsychotic exposure. p-value has been adjusted for multiple testing; no significant result was seen for men. Please note this allele is in LD (with an r-squared greater than 0.89) with rs2497538 and rs1414334. This gene is on the X chromosome, male patients have only one copy. Male and female patients were analyzed separately and together.	olanzapine
655387131	rs951439	PMCID:PMC2194758	RGS4	Genotype CT is associated with increased likelihood of response when treated with olanzapine in people with Schizophrenia.	yes	= 0.007	198		Unknown	Efficacy	false	compared with perphenazine.	olanzapine
655385595	rs1045642	PMID:17038883	ABCB1	Allele A is associated with positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype when treated with olanzapine.	yes	= 0.02	41		Multiple groups, predominantly white	Efficacy	false		olanzapine
1183689318	CYP1A2*1A; CYP1A2*1C	PMID:19000940	CYP1A2	CYP1A2 *1C is not associated with response to olanzapine in people with Schizophrenia as compared to CYP1A2 *1A.	no		130		Central/South Asian	Efficacy	false	no p-value reported	olanzapine
1449181836	rs2229109	PMID:29443543	ABCB1	Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.	yes					Metabolism/PK	false		amisulpride; aripiprazole; olanzapine; risperidone
1448639669	rs1799752	PMCID:PMC5600660	ACE	Allele del is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1451335276	rs10280101	PMID:33378980	ABCB1	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
1183689314	rs1801028	PMID:19000940	DRD2	Allele G is not associated with response to olanzapine in people with Schizophrenia as compared to allele C.	no		130		Central/South Asian	Efficacy	false	no p-value reported	olanzapine
1183491195	rs10214163	PMCID:PMC3845218	SV2C	Genotype TT is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	olanzapine
1446898383	rs17782313	PMID:23920449	MC4R	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	yes	= 0.005	173		Unknown	Other	false	The authors analyzed the whole population of all patients administered one of many anti-psychotics, then a subpopulation without additional weight gain-inducing co-medication (adjusted sub-population) (weight-gaining co-meds included TCA, mirtazapine, lithium, valproic acid, and paroxetine) as well as a sub-group of patients for whom anti-psychotics were given for a first episode. The authors calculated adjusted means for weight gain 4 wk post-initiation of medication using ANCOVA and rs17782313 genotype as a independent variable.	amisulpride; clozapine; olanzapine; paliperidone; quetiapine; risperidone
1451335283	rs11983225	PMID:33378980	ABCB1	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
981478516	rs2497538	PMID:22967772	HTR2C	Allele C is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele A.	yes	= 0.0012	75		European	Toxicity	false	Mental Disorders included borderline-personality disorder, treatment-resistant depression, and bipolar disorder. No patients with schizophrenia were included in order to minimize the amount of previous antipsychotic exposure. p-value has been adjusted for multiple testing; no significant result was seen for men. Please note this allele is in LD (with an r-squared greater than 0.89) with rs6318 and rs1414334. This gene is on the X chromosome, male patients have only one copy. Male and female patients were analyzed separately and together.	olanzapine
1183491199	rs1995381	PMCID:PMC3845218	SV2C	Genotype AA is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	olanzapine
1451335288	rs12720067	PMID:33378980	ABCB1	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
1451317880	rs3842	PMID:33378980	ABCB1	Allele T is associated with increased clearance of olanzapine in healthy individuals as compared to allele C.	yes	= 0.016	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false		olanzapine
1183491185	rs4580760	PMCID:PMC3845218	SV2C	Genotype CC is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AA + AC.	no	= 0.996	134		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	olanzapine
1184469093	rs2412459	PMID:24751813	EIF2AK4	Genotype CT is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype TT.	no	> 0.05	1406		Unknown	Efficacy	false	results did not reach significance.	olanzapine; quetiapine; risperidone; ziprasidone
1451335293	rs4148737	PMID:33378980	ABCB1	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
981478525	rs1414334	PMID:22967772	HTR2C	Allele G is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele C.	yes	= 0.0031	75		European	Toxicity	false	Mental Disorders included borderline-personality disorder, treatment-resistant depression, and bipolar disorder. No patients with schizophrenia were included in order to minimize the amount of previous antipsychotic exposure. p-value has been adjusted for multiple testing; no significant result was seen for men. Please note this allele is in LD (with an r-squared value greater than 0.89) with rs6318 and rs2497538.  This gene is on the X chromosome, male patients have only one copy. Male and female patients were analyzed separately and together.	olanzapine
1451432060	rs1801133	PMID:33858192	MTHFR	Genotype AG is associated with decreased clinical benefit to antipsychotics, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine or risperidone in women with Schizophrenia as compared to genotype GG.	yes	= 0.008	117		Near Eastern	Efficacy	false	"response is measured by PANSS (Positive and Negative Syndrome Scale), alleles complemented to plus chromosomal strand. In initial evaluation of whole cohort (men and women) authors stated ""A
significantly higher mean score was also found in those having MTHFR CT genotype compared with CC and TT
patients. "" ""Higher negative Positive and Negative Syndrome Scale scores were significantly associated with women and having the CT genotype for MTHFR c.677C>T (β = 4.25; p = 0.008) compared with CC patients. """	antipsychotics; chlorpromazine; clozapine; haloperidol; olanzapine; quetiapine; risperidone
981238655	rs17070785	PMCID:PMC3518380	CSMD1	Allele A is associated with response to olanzapine in people with Schizophrenia.	yes	= 1.66E-4	93		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	olanzapine
981479812	rs6960542	PMCID:PMC3100476		Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1451335560	rs3813929	PMID:33378980	HTR2C	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981479819	rs4729562	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
655385601	rs762551	PMID:19636338	CYP1A2	Genotype AA is associated with decreased plasma concentrations when treated with olanzapine in people with psychiatric disorders as compared to allele C.	yes	= 0.001	73		European	Metabolism/PK	false	Association with mean dose-/body weight-normalized serum concentrations.	olanzapine
981479826	rs651430	PMCID:PMC3100476	CYP3A; CYP3A43	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1449731965	rs1045642	PMID:29723928	ABCB1	Genotype AA is not associated with exposure to olanzapine in healthy individuals as compared to genotypes AG + GG.	no	> 0.05	61		Unknown	Metabolism/PK	false	Please note that alleles have been complemented to the positive strand. Genotype at rs1045642 had no statistically significant association with AUC, Cmax, half-life, Tmax, Cl/F or Vd/F of olanzapine.	olanzapine
1451335572	rs815147	PMID:33378980		Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele T.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981940113	rs1045642	PMID:18086475	ABCB1	Genotype AA is associated with increased social and clinical needs when treated with olanzapine in people with Psychotic Disorders as compared to allele G.	yes	= 0.002	28		Multiple groups	Efficacy	false	This significant association between drug response and the variant excited only in patients on olanzapine and was not seen in patients on other antipsychotic drugs included in the study.	olanzapine
1447681374	rs10423928	PMID:25321336	GIPR	Genotypes AA + AT are associated with increased severity of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype TT.	yes	= 0.016	32		East Asian	Toxicity	false	BMI taken at initiation of therapy and at week 4.	olanzapine
1451335577	rs7799039	PMID:33378980	LEP	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
655385610	rs7997012	PMID:19636338	HTR2A	Genotype AA is associated with increased risk of side effects when treated with olanzapine in people with psychiatric disorders as compared to allele G.	yes	= 0.018	50		European	Toxicity	false	P=0.018 for AA vs GA; P=0.002 for AA vs GG	olanzapine
1451335582	rs1137101	PMID:33378980	LEPR	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981479840	rs12535293	PMCID:PMC3100476	CYP3A; CYP3A43	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1451335587	UGT1A1*1; UGT1A1*28	PMID:33378980	UGT1A1	UGT1A1 *28 is not associated with exposure to olanzapine in healthy individuals as compared to UGT1A1 *1.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981479851	rs472660	PMCID:PMC3100476	CYP3A43	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1448255358	rs1414334	PMCID:PMC4941738	HTR2C	Allele C is not associated with risk of Metabolic Syndrome when treated with amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone or ziprasidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to allele G.	no	= 0.164	68	98	European	Toxicity	false	Because HTR2C is on the X chromosome, men and women were analyzed separately.	amisulpride; aripiprazole; clozapine; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
1451147601	rs10264272	PMCID:PMC7235792	CYP3A5	Allele T is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele C.	no		251		Multiple groups, Caucasian, Latin-American, Black and Arab subjects	Metabolism/PK	false	No significant changes in PK parameters in the presence of the C allele. The C allele is also referred to in the paper as the CYP3A5*6 allele.	ambrisentan; aripiprazole; atorvastatin; donepezil; olanzapine
981479862	rs17161981	PMCID:PMC3100476	CYP3A; CYP3A43	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
982015423	rs3813928	PMID:17632216	HTR2C	Allele A is not associated with likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	no		112		European	Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors. There was complete LD between rs3813928 ( – 997) A allele and the rs3813929 ( – 759) T allele.	antipsychotics; clozapine; olanzapine; risperidone
1448631663	FMO3 normal metabolizer genotype	PMID:26856397	FMO3	FMO3 normal metabolizer genotype is not associated with clearance of olanzapine in people with Schizophrenia as compared to FMO3 intermediate metabolizer genotype.	no		21		East Asian	Metabolism/PK	false	no PMs were present. Disease is not specified explicitly but study subjects are referred to as patients and the introduction discusses use of olanzapine as for schizophrenia.	olanzapine
1184169902	UGT1A1*1; UGT1A1*28	PMID:23559402	UGT1A1	UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Fatigue when exposed to olanzapine in healthy individuals as compared to UGT1A1 *1/*1.	yes	= 0.001	63		European	Toxicity	false	A greater percentage of patients with the *1/*28 or *28/*28 genotype experienced fatigue after administration of olanzapine, as compared to those with the *1/*1 genotype. This was significant using the chi-squared test and logistic regression.	olanzapine
827698281	rs10423928	PMID:21747410	GIPR	Genotype AA is associated with increased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to genotypes AT + TT.	yes	< 0.001	60	103	East Asian	Toxicity	false	This genotype effect on insulin was not seen in healthy individuals not taking olanzapine.	olanzapine
1451335100	rs10248420	PMID:33378980	ABCB1	Allele G is associated with increased likelihood of somnolence due to olanzapine in healthy individuals as compared to allele A.	yes	= 0.047	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Toxicity	false		olanzapine
1448631654	CYP2D6 normal metabolizer genotype	PMID:26856397	CYP2D6	CYP2D6 normal metabolizer genotype is not associated with clearance of olanzapine in people with Schizophrenia as compared to CYP2D6 intermediate metabolizer genotype.	no		21		East Asian	Metabolism/PK	false	no PMs (classified as *5/*5 were observed). Disease is not specified explicitly but study subjects are referred to as patients and the introduction discusses use of olanzapine as for schizophrenia.	olanzapine
1451147584	rs41303343	PMCID:PMC7235792	CYP3A5	Allele A is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele del.	no		251		Multiple groups, Caucasian, Latin-American, Black and Arab subjects	Metabolism/PK	false	No significant changes in PK parameters in the presence of the A allele. The A allele is also referred to in the paper as the CYP3A5*7 allele.	ambrisentan; aripiprazole; atorvastatin; donepezil; olanzapine
982015415	rs1414334	PMID:17632216	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	yes	= 0.042	112		European	Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two: although sex by genotype interaction was not significant males with risk haplotype that included this variant had higher OR than females. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors.	antipsychotics; clozapine; olanzapine; risperidone
981479873	rs17161983	PMCID:PMC3100476	CYP3A; CYP3A43	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1451147580	rs35599367	PMCID:PMC7235792	CYP3A; CYP3A4	Allele A is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele G.	no		251		Multiple groups, Caucasian, Latin-American, Black and Arab subjects	Metabolism/PK	false	No significant changes in PK parameters in the presence of the A allele. The A allele is also referred to in the paper as the CYP3A4*22 allele.	ambrisentan; aripiprazole; atorvastatin; donepezil; olanzapine
982015435	rs518147	PMID:17632216	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	no	= 0.049	112		European	Other,Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two: although sex by genotype interaction was not significant males with risk haplotype that included this variant had higher OR than females. This variant was not significant alone for risk of Metabolic Syndrome after bonferroni correction, but waist circumference was significant. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors.	antipsychotics; clozapine; olanzapine; risperidone
1451147572	rs67666821	PMCID:PMC7235792	CYP3A4	Allele T is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele del.	no		251		Multiple groups, Caucasian, Latin-American, Black and Arab subjects	Metabolism/PK	false	No significant changes in PK parameters in the presence of the T allele. The T allele is also referred to in the paper as the CYP3A4*20 allele.	ambrisentan; aripiprazole; atorvastatin; donepezil; olanzapine
981479884	rs2572023	PMCID:PMC3100476	CYP3A	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1184136664	rs9852	PMID:23364847	TBC1D1	Genotype CC is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	yes	= 0.024	114		Multiple groups, European (n=128), African-American (n=55), Other (n=10)	Toxicity	false	"Patients with the CC genotype who were taking either clozapine or olanzapine (""high risk antipsychotic-induced weight gain"" drugs) showed a greater % weight gain during treatment, as compared to those with the CT or TT genotype. Note that no significant results for this SNP were seen when considering the overall sample of patients (n=195; p=0.063), or patients stratified by ethnicity (European or African American only; p=0.139 and p=0.336, respectively) or sex (male or female only; p=0.218 and p=0.052, respectively). Patients were either receiving various antipsychotics (Sample A - 6 weeks and Sample C - 14 weeks) or clozapine only (Sample B - 6 weeks). Please refer to the paper for more info on these treatment groups."	clozapine; olanzapine
982015429	rs3813929	PMID:17632216	HTR2C	Allele C is not associated with likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele T.	no		112		European	Toxicity	false	The gene is on X chromosome therefore males have only one copy, females have two. Data about metabolic parameters at the start of antipsychotic treatment were not available to the authors. There was complete LD between rs3813928 ( – 997) A allele and the rs3813929 ( – 759) T allele.	antipsychotics; clozapine; olanzapine; risperidone
1451335120	CYP3A5*1; CYP3A5*3	PMID:33378980	CYP3A5	CYP3A5 *1/*1 is associated with increased likelihood of somnolence due to olanzapine in healthy individuals as compared to CYP3A5 *1/*3 + *3/*3.	yes	= 0.049	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Toxicity	false	CYP3A5*3 allele identified by genotyping rs776746.	olanzapine
1451147565	rs776746	PMCID:PMC7235792	CYP3A; CYP3A5	Allele C is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele T.	no		251		Multiple groups, Caucasian, Latin-American, Black and Arab subjects	Metabolism/PK	false	No significant changes in PK parameters in the presence of the C allele. The C allele is also referred to in the paper as the CYP3A5*3 allele.	ambrisentan; aripiprazole; atorvastatin; donepezil; olanzapine
981478356	rs2266780	PMID:23147717	FMO3	Genotype GG is associated with decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to genotypes AA + AG.	yes	= 2.0E-4	123		European	Metabolism/PK	false	"Data was from therapeutic drug monitoring service and disease indication for drug use is not specified beyond ""psychiatric patients""."	olanzapine
981479892	rs2527927	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1451147560	rs4986910	PMCID:PMC7235792	CYP3A; CYP3A4	Allele G is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele A.	no		251		Multiple groups, Caucasian, Latin-American, Black and Arab subjects	Metabolism/PK	false	No significant changes in PK parameters in the presence of the G allele. The G allele is also referred to in the paper as the CYP3A4*3 allele.	ambrisentan; aripiprazole; atorvastatin; donepezil; olanzapine
1451158825	rs36120609	PMID:23559402	GSTM3	Genotype TCCTC/TCCTC is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.	yes	< 0.05	63			Metabolism/PK	false	Association described for *A/*A vs *A/*B+*B/*B (del). This result was significant in univariate analysis and multiple regression analysis.	olanzapine
769261698	rs3813929	PMID:21121776	HTR2C	Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.	yes	= 0.006			Multiple groups, Mostly European samples	Other	false	In this meta-analysis, statistical significance was gained when looking at mostly European populations. This gene is on the X chromosome, males on have one copy.	amisulpride; clozapine; haloperidol; iloperidone; olanzapine; quetiapine; risperidone; ziprasidone
1451158820	rs36120609	PMID:23559402	GSTM3	Genotype TCCTC/TCCTC is associated with decreased concentrations of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.	yes	< 0.05	63			Metabolism/PK	false	Association described for *A/*A vs *A/*B+*B/*B (del). This result was ONLY significant in univariate analysis, and NOT significant in multiple regression analysis.	olanzapine
1451335141	rs4728709	PMID:33378980	ABCB1	Genotype GG is associated with increased likelihood of Asthenia due to olanzapine in healthy individuals as compared to genotypes AA + AG.	yes	= 0.045	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Toxicity	false	The only individual in the study cohort to report asthenia had the GG genotype. Please note that alleles have been complimented to the positive strand.	olanzapine
1451335149	rs3842	PMID:33378980	ABCB1	Genotype CC is associated with increased likelihood of Arrhythmias, Cardiac due to olanzapine in healthy individuals as compared to genotypes CT + TT.	yes	= 0.031	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Toxicity	false	The only individual in the study cohort to report palpitations had the CC genotype.	olanzapine
1448999216	rs901865	PMID:23609395	HRH1	Genotypes CC + CT is not associated with increased likelihood of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype TT.	no	= 0.58	70		European	Toxicity	false	BMI change was lower for TT (0.46 compared to 1.33 for CC and 1.13 CT) but SD were large, frequency of T allele was low and study maybe underpowered to detect effects.	olanzapine
1451317740	CYP2C9 poor metabolizers	PMID:33378980	CYP2C9	CYP2C9 poor metabolizers are associated with increased exposure to olanzapine in healthy individuals as compared to CYP2C9 intermediate metabolizer and normal metabolizer.	yes	< 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	CYP2C9 PMs had a significantly increased half-life and Vd/F of olanzapine as compared to CYP2C9 NMs and IMs. The authors identified the CYP2C9*2 and *3 alleles using the SNPs rs1799853 and rs1057910, respectively. Subjects were grouped into phenotype groups using CPIC assignments.	olanzapine
1451335158	rs1045642	PMID:33378980	ABCB1	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. Please note that alleles have been complemented to the positive strand.	olanzapine
1451335160	CYP2C9 poor metabolizers	PMID:33378980	CYP2C9	CYP2C9 poor metabolizers are associated with increased likelihood of Dizziness due to olanzapine in healthy individuals as compared to CYP2C9 intermediate metabolizer and normal metabolizer.	yes	= 0.048	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Toxicity	false	The authors identified the CYP2C9*2 and *3 alleles using the SNPs rs1799853 and rs1057910, respectively. Subjects were grouped into phenotype groups using CPIC assignments.	olanzapine
981501434	rs806378	PMCID:PMC3055343	CNR1	Genotypes CT + TT are associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotype CC.	no	= 0.16	117		European	Toxicity	false	"This was a nominal association that did not survive correction for multiple testing.  The weight gain was 5.96% vs 2.76%.  The association was found in the European ancestry patient subset of this study but not in a larger set that included African-Americans and ""others""."	clozapine; olanzapine
1448998695	rs3813929	PMID:20680028	HTR2C	Allele T is not associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no		186		European	Toxicity	false	Note: this is an x-linked gene so male subjects have only one copy of the allele (T or C) whereas female subjects can be TT, CT or CC.	antipsychotics; aripiprazole; clozapine; olanzapine; quetiapine; risperidone
981478397	rs12720462	PMID:23147717	FMO1	Genotypes AA + AC are associated with increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to genotype CC.	yes	= 0.03	379		European	Metabolism/PK	false	"Data was from therapeutic drug monitoring service and disease indication for drug use is not specified beyond ""psychiatric patients"". This was more significant when considered with rs7877T, and more pronounced in smokers."	olanzapine
1183703820	rs1800497	PMID:23559402	ANKK1	Genotype GG is associated with decreased area under the curve from baseline to the last measured concentration when exposed to olanzapine in healthy individuals as compared to genotypes AA + AG.	yes	= 0.02	63		European	Other	false	G = A2, A = A1. Patients with the GG genotype had decreased area under the curve from baseline to the last measured concentration (iAUC) as compared to people with AA or AG genotype.	olanzapine
1448998876	rs3813928	PMID:20504252	HTR2C	Genotype GG is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + AG.	yes	= 0.038	62	66	European	Toxicity	false	Groups compared were GG females plus G males vs AG females + AA females + A males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1451335424	CYP3A5*1; CYP3A5*3	PMID:33378980	CYP3A5	CYP3A5 *3 is not associated with exposure to olanzapine in healthy individuals as compared to CYP3A5 *1.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes. rs776746 was used to identify the *3 allele.	olanzapine
608431041	rs3813929	PMID:19434072	HTR2C	Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele C.	yes	< 0.025	107		European	Toxicity	false	defined as >or=10% increase in body mass index. This gene is on the X chromosome, males have only one copy. T carriers: TT female, CT females and T males were compared to those with no T alleles: CC females and C males.	olanzapine
1451335427	rs1799732	PMID:33378980	DRD2	Genotype GG is not associated with exposure to olanzapine in healthy individuals as compared to genotype G/del.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1451335433	rs6280	PMID:33378980	DRD3	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1183703815	rs1800497	PMID:23559402	ANKK1	Genotype GG is associated with decreased peak plasma concentration of increased prolactin when exposed to olanzapine in healthy individuals as compared to genotypes AA + AG.	yes	= 0.024	63		European	Other	false	G = A2, A = A1. Patients with the GG genotype had decreased peak plasma concentration of increased prolactin (iCmax; ng/mL) as compared to people with AA or AG genotype.	olanzapine
1451151860	rs6313	PMID:32462699	HTR2A	Genotypes AA + AG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype GG.	yes	= 0.046	100		European	Efficacy	false	Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly better response in the Emsley's positive dimension was observed in carriers of the A allele. Please note that alleles have been complemented to the positive strand.	olanzapine
1448997846	rs3813929	PMID:25152019	HTR2C	Allele C is associated with increased severity of Weight gain when treated with olanzapine in people with schizoaffective disorder and Schizophrenia as compared to allele T.	no	= 0.58	257		European	Toxicity	false	This was not significant but authors call it a trend in the subset of Caucasian patients receiving olanzapine. Article has typo in rs number and lists rs3813829 as equivalent to -759C>T. Corrected here to the appropriate rs number. This gene is on the X chromosome and analysis was done for presence of T allele vs absence of T allele.	olanzapine
1183703811	rs1695	PMID:23559402	GSTP1	Genotype AA is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes AG + GG.	yes	< 0.05	63		European	Metabolism/PK	false	A = *A and G = *B. This result was ONLY significant in univariate analysis, and NOT significant in multiple regression analysis.	olanzapine
981479695	rs472660	PMCID:PMC3100476	CYP3A43	Genotype AA is associated with increased clearance of olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	yes	= 1.5E-5	235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Dosage,Efficacy,Metabolism/PK,Toxicity	false		olanzapine
1448998866	rs498207	PMID:20504252	HTR2C	Genotype AA is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.	yes	= 0.0196	62	66	European	Toxicity	false	Groups compared were AA females plus A males vs AG females + GG females + G males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1183703835	CYP2C9*1; CYP2C9*2; CYP2C9*3; CYP2C9*6	PMID:23559402	CYP2C9	CYP2C9 *1/*3 + *2/*3 + *3/*6 is associated with increased likelihood of Hypotension when exposed to olanzapine in healthy individuals as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2.	yes	= 0.016	63		European	Toxicity	false	A greater percentage of patients with the *1/*3, *2/*3 or *3/*6 genotype experienced hypotension after administration of olanzapine, as compared to those with the *1/*1, *1/*2 or *2/*2 genotype. This was significant using the chi-squared test and logistic regression.	olanzapine
1451151848	rs6313	PMID:32462699	HTR2A	Genotypes AG + GG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype AA.	yes	= 0.03	100		European	Efficacy	false	Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly better response in the Emsley's anxiety factor was observed in carriers of the G allele. Please note that alleles have been complemented to the positive strand.	olanzapine
1451335447	rs6277	PMID:33378980	DRD2	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1448997834	rs3813929	PMID:25152019	HTR2C	Allele C is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele T.	no	= 0.34	843		Multiple groups, Mostly Caucasian, ranging from 88% white to 100% white cases, one study Korean Asian, one unknown,	Toxicity	false	Article has typo in rs number and lists rs3813829 as equivalent to -759C>T. Corrected here to the appropriate rs number. This gene is on the X chromosome and analysis was done for presence of T allele vs absence of T allele.	clozapine; olanzapine; risperidone
981475608	rs10042486	PMID:22120873	HTR1A	Genotype TT is associated with increased response to amisulpride, antipsychotics, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 1.0E-6	221		East Asian	Efficacy	false	Response was measured by difference in PANSS scores between admission and discharge. Subjects with the TT genotype were more likely to improve on the PANSS total, positive and negative scores as compared to the CC + CT genotypes. Percentages of study participants taking each drug are as follow: risperidone (34%), olanzapine (24%), quetiapine (6%), amisulpiride (15%), and other antipsychotics (4%).	amisulpride; antipsychotics; olanzapine; quetiapine; risperidone
1183703824	TPMT*1; TPMT*3A; TPMT*3C	PMID:23559402	TPMT	TPMT *1/*3A + *1/*3C is associated with increased likelihood of Fatigue when exposed to olanzapine in healthy individuals as compared to TPMT *1/*1.	yes	= 0.012	63		European	Toxicity	false	A greater percentage of patients with the *1/*3A or *1/*3C genotype experienced fatigue after administration of olanzapine, as compared to those with the *1/*1 genotype. This was significant using the chi-squared test and logistic regression.	olanzapine
1451335452	rs6314	PMID:33378980	HTR2A	Genotype AG is not associated with exposure to olanzapine in healthy individuals as compared to genotype GG.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
1448998908	rs10490624	PMID:20504252	INSIG2	Genotype TT is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotype CT.	no	= 0.0196	62	66	European	Toxicity	false	No CC homozygotes in sample set.	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1451335460	rs2108622	PMID:33378980	CYP4F2	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981479718	rs2472300	PMCID:PMC3100476	CYP1A2	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1184000309	rs1800497	PMID:23859574	ANKK1	Genotype AA is associated with increased gastrointestinal toxicity when treated with olanzapine in healthy individuals as compared to genotypes AG + GG.	not stated	= 0.033	58		European	Toxicity	false	Individuals with the DRD2 A1/A1 genotype more frequently developed gastrointestinal adverse reactions (40%) vs A1/A2 (5.5%) and A2/A2 (6%). Here allele A is used to represent A1 which is less frequent in Caucasian populations  and G to represent A2 which is the major allele in Caucasians). Statistics did not mention correction for multiple testing.	olanzapine
1449000436	rs3813929	PMID:19193342	HTR2C	Allele T is not associated with increased severity of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	no	= 0.20	164		East Asian	Toxicity	false	This gene is on the X chromosome and males only have one copy. Study compared minor allele absent (C or CC) vs minor allele present (T, CT or TT), % change in BMI was around 5% for both groups.	olanzapine
1448998900	rs17587100	PMID:20504252	INSIG2	Genotype AA is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1451335464	rs6313	PMID:33378980	HTR2A	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981479724	rs2069522	PMCID:PMC3100476	CYP1A2	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1184168762	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:20031235	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	yes	= 0.05	147		European	Efficacy	false	The L/S (Long/Short) genotype was associated with better negative symptom response to antipsychotic treatment, especially olanzapine, than either of the homozygous genotypes were.  This article described the alleles only as L and S- not clear on exact sequence.  Association was significant for the SANS but not the BPRS or SAPS. 6 week response was assessed.	antipsychotics; haloperidol; olanzapine; risperidone
769261685	rs518147	PMID:21121776	HTR2C	Allele G is associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine and risperidone in people with Schizophrenia as compared to allele C.	yes	= 0.019	205		Multiple groups	Other	false	A significant association was not found with genotypes groups but when women were analyzed separately there is a borderline p value. This gene is on the X chromosome and males have only one copy, so genotypes are G and C. Of the CC women (n=6) zero were in the weight gain group, 7 of 27 CG women gained weight whereas 14 of 29 GG women gained weight.	clozapine; haloperidol; olanzapine; risperidone
1448998892	rs7799039	PMID:20504252	LEP	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + AG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
981479730	rs2069526	PMCID:PMC3100476	CYP1A2	Allele G is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1448997871	rs7799039	PMID:18515891	LEP	Genotypes AG + GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with Schizophrenia as compared to genotype AA.	yes	= 0.032	120		Unknown	Toxicity	false	Variant referred to in paper as -2548A/G	clozapine; olanzapine; risperidone
1447679482	rs723672	PMID:26049408	CACNA1C	Allele C is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.16	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
982015292	rs11111201	PMID:17541984	PMCH	Allele G is not associated with increased likelihood of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele A.	no		72	149	European	Other	false	Obesity. Subjects were classified into one of three groups: obese, overweight or normal weight	olanzapine
981479737	rs4646425	PMCID:PMC3100476	CYP1A2	Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1448998884	rs3813929	PMID:20504252	HTR2C	Genotype CC is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CT + TT.	yes	= 0.04	62	66	European	Toxicity	false	Groups compared were CC females plus C males vs CT females + TT females + T males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1183703862	TPMT*1; TPMT*3A; TPMT*3C	PMID:23559402	TPMT	TPMT *1/*3A + *1/*3C is associated with increased likelihood of Dizziness when exposed to olanzapine in healthy individuals as compared to TPMT *1/*1.	yes	= 0.019	63		European	Toxicity	false	A greater percentage of patients with the *1/*3A or *1/*3C genotype experienced dizziness after administration of olanzapine, as compared to those with the *1/*1 genotype. This was ONLY significant using the chi-squared test, and was NOT significant using logistic regression.	olanzapine
1447987701	rs1415744	PMID:27092952	EPM2A	Allele C is associated with increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone or trifluoperazine in people with Schizophrenia as compared to allele T.	yes	= 0.02	573		East Asian	Efficacy	false	Symptom improvement measured by PANSS score (Positive and Negative Symptom Scale) after 20-40 days of treatment. The CC genotype was associated with an improved response compared to CT, which was also associated with an improved response compared to TT. The CG haplotype of rs1415744 and rs702304 was associated with improvement on the negative symptom scale (p=0.02).	chlorpromazine; clozapine; haloperidol; olanzapine; quetiapine; risperidone; trifluoperazine
982015286	rs7973796	PMID:17541984	PMCH	Allele G is associated with increased likelihood of obesity when treated with olanzapine in people with Schizophrenia as compared to allele A.	yes	= 0.023	72	149	European	Other	false	The association was found for patients age 50 and under, but not for patients over age 50.  Subjects were classified into one of three groups: obese, overweight or normal weight.   Compared to controls, GG (OR 10.19 [95% CI: 1.05, infinity] > GA (OR 4.35 [95% CI 0.59,infinity] ) > AA (.26 [OR 0, 2.71]).	olanzapine
1447679991	rs2283271	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.07	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
981479744	rs11631682	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
769246747	rs2228622	PMID:19884611	SLC1A1	Allele A is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.	yes	= 0.04	40	54	East Asian	Toxicity	false	"In this pharmacogenetic case-control study of outpatient schizophrenic clinic, trends of association were observed in rs2228622 and rs3780412 (nominal P=.01; adjusted permutation P=.07) for the dominant model that was the inheritance model that best fit our data. In the haplotype-based analysis, the A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with AAP-induced OC symptoms; this association
withstood multiple test correction (nominal
P=.01; adjusted permutation P=.04; odds ratio,3.955; 95% confidence interval, 1.366-11.452, for dominant model)."	clozapine; olanzapine; risperidone
981479749	rs6002616	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
769246751	rs3780413	PMID:19884611	SLC1A1	Allele G is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.	yes	= 0.04	40	54	East Asian	Toxicity	false	"In this pharmacogenetic case-control study of outpatient schizophrenic clinic, trends of association were observed in rs2228622 and rs3780412 (nominal P=.01; adjusted permutation P=.07) for the dominant model that was the inheritance model that best fit our data. In the haplotype-based analysis, the A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with AAP-induced OC symptoms; this association
withstood multiple test correction (nominal
P=.01; adjusted permutation P=.04; odds ratio,3.955; 95% confidence interval, 1.366-11.452, for dominant model)."	clozapine; olanzapine; risperidone
1448998811	rs3813928	PMID:17016522	HTR2C	Allele A is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no		138		European	Toxicity	false	Authors state this SNP only significant as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C/rs3813928 G, rs518147 C and rs1414334 C. This SNP was in linkage with rs3813929 (-759 C/T), with T and A found together. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone
1448998293	rs3813929	PMID:18515891	HTR2C	Allele C is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.97	120		Unknown	Toxicity	false	Variant is described as -759C/T. As the 5-HT2C receptor gene is linked to the X chromosome, male participants were genotyped hemizygotes C or T with 15 of 84 (18%) having the T allele. Among female participants, 15 of 45 (33%) were heterozygotic; none were homozygous for the T allele.	clozapine; olanzapine; risperidone
981479756	rs9306356	PMCID:PMC3100476		Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1183703872	rs1695	PMID:23559402	GSTP1	Genotype AA is associated with increased likelihood of Syncope when exposed to olanzapine in healthy individuals as compared to genotypes AG + GG.	yes	= 0.006	63		European	Toxicity	false	A = *A and G = *B. A greater percentage of patients with the AA genotype experienced syncope after administration of olanzapine, as compared to those with the AG or GG genotype. This was ONLY significant using the chi-squared test, and was NOT significant using logistic regression.	olanzapine
1183864130	rs472660	PMID:24595013	CYP3A43	Genotype AA is not associated with differences in dose-adjusted trough serum olanzapine concentrations when treated with olanzapine in people with Mental Disorders as compared to genotypes AG + GG.	no	= 0.23	374		European	Metabolism/PK	false	Only seven patients were AA carriers. P-values:  without (P=0.6) or with (P=0.23) adjustment for additional covariates.	olanzapine
1448998799	rs3813929	PMID:17016522	HTR2C	Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	no		138		European	Toxicity	false	Authors state this SNP only significant as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C, rs518147 C and rs1414334 C. This SNP was in linkage with rs3813928 (-997 G/A), with T and A found together. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone
981479763	rs2213712	PMCID:PMC3100476		Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
981479768	rs2859228	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1448998790	rs1414334	PMID:17016522	HTR2C	Allele C is associated with increased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	yes		138		European	Toxicity	false	Authors state this SNP was significant alone and as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C, rs518147 C and rs1414334 C. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone
981238689	rs221253	PMCID:PMC3518380	PTPRN2	Allele C is associated with response to olanzapine in people with Schizophrenia.	yes	= 3.33E-4	93		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	olanzapine
981479773	rs2859229	PMCID:PMC3100476		Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1451335520	rs7997012	PMID:33378980	HTR2A	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981479778	rs1492899	PMCID:PMC3100476		Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1448997822	rs518147	PMID:25152019	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	yes	= 0.05	422		Multiple groups, Two studies that were mostly Caucasian, ranging from 88% white to >95% white cases and one in Korean Asian cases	Toxicity	false	"Authors note significance as ""marginal"". This gene is on the X chromosome and analysis was done for presence of C allele vs absence of C allele."	clozapine; olanzapine; risperidone
1446896603	rs6265	PMID:24595507	BDNF	Genotype CC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	yes	= 0.032	214		European	Efficacy	false	The CC genotype (referred to as Val/Val in the paper) was associated with an increased likelihood of response to olanzapine treatment, as compared to those with the CT or TT genotype (Val/Met or Met/Met). Response defined as at least a 50% reduction in the initial Positive and Negative Syndrome Scale (PANSS) total and subscale scores after 8 weeks of treatment. Significant results were seen for the PANSS total and PANSS positive subscale scores, but not for PANSS negative or PANSS general psychopathology scores.	olanzapine
981479783	rs929087	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
608431018	rs6313	PMID:19494443	HTR2A	Allele A is associated with increased risk of treatment-resistance when treated with olanzapine and risperidone in people with Alzheimer Disease as compared to allele G.	not stated		80		European	Efficacy	false		olanzapine; risperidone
1448997808	rs1414334	PMID:25152019	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	yes	= 0.0004	462		Multiple groups, Mostly Caucasian, ranging from 88% white to >95% white cases	Toxicity	false	This gene is on the X chromosome and analysis was done for presence of C allele vs absence of C allele.	clozapine; olanzapine; risperidone
981479790	rs10458360	PMCID:PMC3100476		Allele C is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
981238675	rs3819811	PMCID:PMC3518380	PLAGL1	Allele A is associated with response to olanzapine in people with Schizophrenia.	yes	= 2.43E-4	93		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	olanzapine
608431026	rs3813929	PMID:19636338	HTR2C	Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Depressive Disorder or Schizophrenia as compared to allele C.	yes	= 0.011	56		European	Toxicity	false	Association with short-term weight gain. This gene is on the X chromosome. Study compared TT/CT women plus T men vs CC women plus C men. Overall study had 36 men and 37 women but did not clarify how many were included in weight gain analysis.	olanzapine
981479797	rs2527894	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
1451335540	rs1414334	PMID:33378980	HTR2C	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele C.	no	> 0.05	80		"Multiple groups, ""36 Caucasians, 42 Latin-Americans and 2 Blacks"""	Metabolism/PK	false	No significant difference in a number of pharmacokinetic parameters was found between genotypes.	olanzapine
981238661	rs2247408	PMCID:PMC3518380	PLAGL1	Allele C is associated with response to olanzapine in people with Schizophrenia.	yes	= 2.07E-4	93		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	olanzapine
769246755	rs3780412	PMID:19884611	SLC1A1	Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.	yes	= 0.04	40	54	East Asian	Toxicity	false	In this pharmacogenetic case-control study of outpatient schizophrenic clinic, trends of association were observed in rs2228622 and rs3780412 (nominal P=.01; adjusted permutation P=.07) for the dominant model that was the inheritance model that best fit our data. In the haplotype-based analysis, the A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with AAP-induced OC symptoms; this association withstood multiple test correction (nominal P=.01; adjusted permutation P=.04; odds ratio,3.955; 95% confidence interval, 1.366-11.452, for dominant model).	clozapine; olanzapine; risperidone
981479802	rs2527887	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele T.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine
608431038	rs3813929	PMID:15666332	HTR2C	Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele C.	yes	= 0.0035	42		European	Toxicity	false	This gene is on the X chromosome, with males having only one copy. The frequency of the T allele was 17.6% in the male subjects and 31% in the female subjects. All of the subjects, who gained >10% of their initial body weight over 6 weeks, had at least one C allele.	olanzapine
769181734	rs518147	PMID:19434072	HTR2C	Allele C is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele G.	yes	< 0.025	107		European	Toxicity	false	defined as >or=10% increase in body mass index. This gene is on the X chromosome, males have only one copy. C carriers: CC female, CG females and C males were compared to those with no C alleles: GG females and G males.	olanzapine
1448997283	rs680055	PMID:25150845	CYP3A43	Genotype CG is associated with increased response to antipsychotics, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to genotype CC.	yes	= 0.013	152		European	Efficacy	false	No GG homozygotes were observed. Approximately 50% of patients were receiving clozapine, the rest had other antipsychotics including risperidone (N = 25), olanzapine (N = 16), haloperidol (N = 7), amisulpride (N = 6), aripiprazole (N = 15), ziprasidone (N = 1), fluphenazine (N = 1) and quetiapine (N = 5)	antipsychotics; aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1448998819	rs518147	PMID:17016522	HTR2C	Allele C is associated with increased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no		138		European	Toxicity	false	Authors state this SNP only significant as part of group of HTR2C:c.1-142948(GT)n 13 repeat allele, rs3813929 C/rs3813928 G, rs518147 C and rs1414334 C. The HTR2C gene is on the X chromosome and therefore males only have one copy. Sample set was 63% males.	antipsychotics; clozapine; olanzapine; risperidone
981479807	rs2525557	PMCID:PMC3100476		Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	no		235		Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.	Metabolism/PK	false		olanzapine